Pharmacogenomic profiling of variants affecting efficacy and toxicity of anti-infective medicines in a south Asian population from Sri Lanka
Background Anti-infective medicines are crucial for treating infections, but improper dosing can cause toxicity, resistance and treatment failure. Pharmacogenomics can address genetic variations affecting drug efficacy and safety. Despite the high burden of diseases like TB and HIV in Sri Lanka and...
Uložené v:
| Vydané v: | BMC infectious diseases Ročník 25; číslo 1; s. 153 - 12 |
|---|---|
| Hlavní autori: | , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
London
BioMed Central
01.02.2025
BioMed Central Ltd BMC |
| Predmet: | |
| ISSN: | 1471-2334, 1471-2334 |
| On-line prístup: | Získať plný text |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Background
Anti-infective medicines are crucial for treating infections, but improper dosing can cause toxicity, resistance and treatment failure. Pharmacogenomics can address genetic variations affecting drug efficacy and safety. Despite the high burden of diseases like TB and HIV in Sri Lanka and South Asia, pharmacogenomic data for these populations are limited. This study aims to fill this gap by investigating pharmacogenomic variants in a South Asian population from Sri Lankan.
Methods
Pharmacogenomic data on anti-infective medicines were obtained from the PharmGKB database, selecting variants with evidence levels 1 A, 1B, 2 A, and 2B. Sri Lankan genetic data were sourced from an anonymized database of 670 Sri Lankans maintained by the Centre for Genetics and Genomics, Faculty of Medicine, University of Colombo. MAFs were compared between Sri Lankan sub-populations and global data from gnomAD, with statistical significance set at
p
< 0.05.
Results
MAFs of
NAT2
gene rs1041983 and rs1799931 variants were, 43.7% (95%CI:41.1–46.4), 7.3% (95%CI:6.0-8.8), respectively. The
UGT1A1
rs4148323 variant had a MAF of 3.5% (95%CI:2.6–4.6). In the
CYP2B6
gene, 109 individuals were homozygous for the rs3745274 (poor metaboliser) variant, with a MAF of 39.6% (95%CI:37.0-42.3), while the rs34097093 and rs28399499 variants had no individuals homozygous for the variant (MAF: 0.2% [95%CI:0-0.5] (poor/intermediate metaboliser), and 0.1% [95%CI:0-0.4] (poor/intermediate metaboliser), respectively). The MAFs of the
CYP2C19
rs12769205 (poor/intermediate metaboliser), rs4244285 (poor/intermediate metaboliser), rs3758581 (poor/intermediate metaboliser), and rs4986893 (poor/intermediate metaboliser) variants were 41.9% (95%CI:39.3–44.6), 41.9% (95%CI:39.2–44.7), 9.7% (95%CI:8.2–11.4), and 0.5% [(95%CI:0.2–1.1), respectively. Most variants showed significant differences compared to global populations, with some exhibiting higher frequencies, particularly when compared to Europeans.
CYP2C19
rs12769205 and rs4244285 exhibited higher MAFs in Sri Lankans compared to both other South Asians and Europeans. The
NAT2
rs1041983,
NAT2
rs1799931,
CYP2C19
rs4986893,
CYP2C19
rs3758581, and
CYP2B6
rs3745274 variants demonstrated significantly higher MAFs than in Europeans but not significantly different from South Asians.
Conclusion
This preliminary study identifies variants in
NAT2
,
UGT1A1
,
CYP2B6
, and
CYP2C19
genes relevant to the metabolism of anti-TB drugs, antiretrovirals, and voriconazole among Sri Lankans. Several variants, including
CYP2C19
rs12769205 and rs4244285, showed higher MAFs, particularly in comparison to European populations, indicating potential differences in drug response. However, the nature of the study limits the ability to explore clinical correlations with the genotypes, therefore further research focusing on clinical correlation and functional validation is required. |
|---|---|
| AbstractList | Background
Anti-infective medicines are crucial for treating infections, but improper dosing can cause toxicity, resistance and treatment failure. Pharmacogenomics can address genetic variations affecting drug efficacy and safety. Despite the high burden of diseases like TB and HIV in Sri Lanka and South Asia, pharmacogenomic data for these populations are limited. This study aims to fill this gap by investigating pharmacogenomic variants in a South Asian population from Sri Lankan.
Methods
Pharmacogenomic data on anti-infective medicines were obtained from the PharmGKB database, selecting variants with evidence levels 1 A, 1B, 2 A, and 2B. Sri Lankan genetic data were sourced from an anonymized database of 670 Sri Lankans maintained by the Centre for Genetics and Genomics, Faculty of Medicine, University of Colombo. MAFs were compared between Sri Lankan sub-populations and global data from gnomAD, with statistical significance set at
p
< 0.05.
Results
MAFs of
NAT2
gene rs1041983 and rs1799931 variants were, 43.7% (95%CI:41.1–46.4), 7.3% (95%CI:6.0-8.8), respectively. The
UGT1A1
rs4148323 variant had a MAF of 3.5% (95%CI:2.6–4.6). In the
CYP2B6
gene, 109 individuals were homozygous for the rs3745274 (poor metaboliser) variant, with a MAF of 39.6% (95%CI:37.0-42.3), while the rs34097093 and rs28399499 variants had no individuals homozygous for the variant (MAF: 0.2% [95%CI:0-0.5] (poor/intermediate metaboliser), and 0.1% [95%CI:0-0.4] (poor/intermediate metaboliser), respectively). The MAFs of the
CYP2C19
rs12769205 (poor/intermediate metaboliser), rs4244285 (poor/intermediate metaboliser), rs3758581 (poor/intermediate metaboliser), and rs4986893 (poor/intermediate metaboliser) variants were 41.9% (95%CI:39.3–44.6), 41.9% (95%CI:39.2–44.7), 9.7% (95%CI:8.2–11.4), and 0.5% [(95%CI:0.2–1.1), respectively. Most variants showed significant differences compared to global populations, with some exhibiting higher frequencies, particularly when compared to Europeans.
CYP2C19
rs12769205 and rs4244285 exhibited higher MAFs in Sri Lankans compared to both other South Asians and Europeans. The
NAT2
rs1041983,
NAT2
rs1799931,
CYP2C19
rs4986893,
CYP2C19
rs3758581, and
CYP2B6
rs3745274 variants demonstrated significantly higher MAFs than in Europeans but not significantly different from South Asians.
Conclusion
This preliminary study identifies variants in
NAT2
,
UGT1A1
,
CYP2B6
, and
CYP2C19
genes relevant to the metabolism of anti-TB drugs, antiretrovirals, and voriconazole among Sri Lankans. Several variants, including
CYP2C19
rs12769205 and rs4244285, showed higher MAFs, particularly in comparison to European populations, indicating potential differences in drug response. However, the nature of the study limits the ability to explore clinical correlations with the genotypes, therefore further research focusing on clinical correlation and functional validation is required. Anti-infective medicines are crucial for treating infections, but improper dosing can cause toxicity, resistance and treatment failure. Pharmacogenomics can address genetic variations affecting drug efficacy and safety. Despite the high burden of diseases like TB and HIV in Sri Lanka and South Asia, pharmacogenomic data for these populations are limited. This study aims to fill this gap by investigating pharmacogenomic variants in a South Asian population from Sri Lankan. Pharmacogenomic data on anti-infective medicines were obtained from the PharmGKB database, selecting variants with evidence levels 1 A, 1B, 2 A, and 2B. Sri Lankan genetic data were sourced from an anonymized database of 670 Sri Lankans maintained by the Centre for Genetics and Genomics, Faculty of Medicine, University of Colombo. MAFs were compared between Sri Lankan sub-populations and global data from gnomAD, with statistical significance set at p < 0.05. MAFs of NAT2 gene rs1041983 and rs1799931 variants were, 43.7% (95%CI:41.1-46.4), 7.3% (95%CI:6.0-8.8), respectively. The UGT1A1 rs4148323 variant had a MAF of 3.5% (95%CI:2.6-4.6). In the CYP2B6 gene, 109 individuals were homozygous for the rs3745274 (poor metaboliser) variant, with a MAF of 39.6% (95%CI:37.0-42.3), while the rs34097093 and rs28399499 variants had no individuals homozygous for the variant (MAF: 0.2% [95%CI:0-0.5] (poor/intermediate metaboliser), and 0.1% [95%CI:0-0.4] (poor/intermediate metaboliser), respectively). The MAFs of the CYP2C19 rs12769205 (poor/intermediate metaboliser), rs4244285 (poor/intermediate metaboliser), rs3758581 (poor/intermediate metaboliser), and rs4986893 (poor/intermediate metaboliser) variants were 41.9% (95%CI:39.3-44.6), 41.9% (95%CI:39.2-44.7), 9.7% (95%CI:8.2-11.4), and 0.5% [(95%CI:0.2-1.1), respectively. Most variants showed significant differences compared to global populations, with some exhibiting higher frequencies, particularly when compared to Europeans. CYP2C19 rs12769205 and rs4244285 exhibited higher MAFs in Sri Lankans compared to both other South Asians and Europeans. The NAT2 rs1041983, NAT2 rs1799931, CYP2C19 rs4986893, CYP2C19 rs3758581, and CYP2B6 rs3745274 variants demonstrated significantly higher MAFs than in Europeans but not significantly different from South Asians. This preliminary study identifies variants in NAT2, UGT1A1, CYP2B6, and CYP2C19 genes relevant to the metabolism of anti-TB drugs, antiretrovirals, and voriconazole among Sri Lankans. Several variants, including CYP2C19 rs12769205 and rs4244285, showed higher MAFs, particularly in comparison to European populations, indicating potential differences in drug response. However, the nature of the study limits the ability to explore clinical correlations with the genotypes, therefore further research focusing on clinical correlation and functional validation is required. Background Anti-infective medicines are crucial for treating infections, but improper dosing can cause toxicity, resistance and treatment failure. Pharmacogenomics can address genetic variations affecting drug efficacy and safety. Despite the high burden of diseases like TB and HIV in Sri Lanka and South Asia, pharmacogenomic data for these populations are limited. This study aims to fill this gap by investigating pharmacogenomic variants in a South Asian population from Sri Lankan. Methods Pharmacogenomic data on anti-infective medicines were obtained from the PharmGKB database, selecting variants with evidence levels 1 A, 1B, 2 A, and 2B. Sri Lankan genetic data were sourced from an anonymized database of 670 Sri Lankans maintained by the Centre for Genetics and Genomics, Faculty of Medicine, University of Colombo. MAFs were compared between Sri Lankan sub-populations and global data from gnomAD, with statistical significance set at p < 0.05. Results MAFs of NAT2 gene rs1041983 and rs1799931 variants were, 43.7% (95%CI:41.1-46.4), 7.3% (95%CI:6.0-8.8), respectively. The UGT1A1 rs4148323 variant had a MAF of 3.5% (95%CI:2.6-4.6). In the CYP2B6 gene, 109 individuals were homozygous for the rs3745274 (poor metaboliser) variant, with a MAF of 39.6% (95%CI:37.0-42.3), while the rs34097093 and rs28399499 variants had no individuals homozygous for the variant (MAF: 0.2% [95%CI:0-0.5] (poor/intermediate metaboliser), and 0.1% [95%CI:0-0.4] (poor/intermediate metaboliser), respectively). The MAFs of the CYP2C19 rs12769205 (poor/intermediate metaboliser), rs4244285 (poor/intermediate metaboliser), rs3758581 (poor/intermediate metaboliser), and rs4986893 (poor/intermediate metaboliser) variants were 41.9% (95%CI:39.3-44.6), 41.9% (95%CI:39.2-44.7), 9.7% (95%CI:8.2-11.4), and 0.5% [(95%CI:0.2-1.1), respectively. Most variants showed significant differences compared to global populations, with some exhibiting higher frequencies, particularly when compared to Europeans. CYP2C19 rs12769205 and rs4244285 exhibited higher MAFs in Sri Lankans compared to both other South Asians and Europeans. The NAT2 rs1041983, NAT2 rs1799931, CYP2C19 rs4986893, CYP2C19 rs3758581, and CYP2B6 rs3745274 variants demonstrated significantly higher MAFs than in Europeans but not significantly different from South Asians. Conclusion This preliminary study identifies variants in NAT2, UGT1A1, CYP2B6, and CYP2C19 genes relevant to the metabolism of anti-TB drugs, antiretrovirals, and voriconazole among Sri Lankans. Several variants, including CYP2C19 rs12769205 and rs4244285, showed higher MAFs, particularly in comparison to European populations, indicating potential differences in drug response. However, the nature of the study limits the ability to explore clinical correlations with the genotypes, therefore further research focusing on clinical correlation and functional validation is required. Keywords: Anti-infectives, Sri Lanka, South Asia, Pharmacogenomics, Tuberculosis, HIV, Voriconazole Anti-infective medicines are crucial for treating infections, but improper dosing can cause toxicity, resistance and treatment failure. Pharmacogenomics can address genetic variations affecting drug efficacy and safety. Despite the high burden of diseases like TB and HIV in Sri Lanka and South Asia, pharmacogenomic data for these populations are limited. This study aims to fill this gap by investigating pharmacogenomic variants in a South Asian population from Sri Lankan.BACKGROUNDAnti-infective medicines are crucial for treating infections, but improper dosing can cause toxicity, resistance and treatment failure. Pharmacogenomics can address genetic variations affecting drug efficacy and safety. Despite the high burden of diseases like TB and HIV in Sri Lanka and South Asia, pharmacogenomic data for these populations are limited. This study aims to fill this gap by investigating pharmacogenomic variants in a South Asian population from Sri Lankan.Pharmacogenomic data on anti-infective medicines were obtained from the PharmGKB database, selecting variants with evidence levels 1 A, 1B, 2 A, and 2B. Sri Lankan genetic data were sourced from an anonymized database of 670 Sri Lankans maintained by the Centre for Genetics and Genomics, Faculty of Medicine, University of Colombo. MAFs were compared between Sri Lankan sub-populations and global data from gnomAD, with statistical significance set at p < 0.05.METHODSPharmacogenomic data on anti-infective medicines were obtained from the PharmGKB database, selecting variants with evidence levels 1 A, 1B, 2 A, and 2B. Sri Lankan genetic data were sourced from an anonymized database of 670 Sri Lankans maintained by the Centre for Genetics and Genomics, Faculty of Medicine, University of Colombo. MAFs were compared between Sri Lankan sub-populations and global data from gnomAD, with statistical significance set at p < 0.05.MAFs of NAT2 gene rs1041983 and rs1799931 variants were, 43.7% (95%CI:41.1-46.4), 7.3% (95%CI:6.0-8.8), respectively. The UGT1A1 rs4148323 variant had a MAF of 3.5% (95%CI:2.6-4.6). In the CYP2B6 gene, 109 individuals were homozygous for the rs3745274 (poor metaboliser) variant, with a MAF of 39.6% (95%CI:37.0-42.3), while the rs34097093 and rs28399499 variants had no individuals homozygous for the variant (MAF: 0.2% [95%CI:0-0.5] (poor/intermediate metaboliser), and 0.1% [95%CI:0-0.4] (poor/intermediate metaboliser), respectively). The MAFs of the CYP2C19 rs12769205 (poor/intermediate metaboliser), rs4244285 (poor/intermediate metaboliser), rs3758581 (poor/intermediate metaboliser), and rs4986893 (poor/intermediate metaboliser) variants were 41.9% (95%CI:39.3-44.6), 41.9% (95%CI:39.2-44.7), 9.7% (95%CI:8.2-11.4), and 0.5% [(95%CI:0.2-1.1), respectively. Most variants showed significant differences compared to global populations, with some exhibiting higher frequencies, particularly when compared to Europeans. CYP2C19 rs12769205 and rs4244285 exhibited higher MAFs in Sri Lankans compared to both other South Asians and Europeans. The NAT2 rs1041983, NAT2 rs1799931, CYP2C19 rs4986893, CYP2C19 rs3758581, and CYP2B6 rs3745274 variants demonstrated significantly higher MAFs than in Europeans but not significantly different from South Asians.RESULTSMAFs of NAT2 gene rs1041983 and rs1799931 variants were, 43.7% (95%CI:41.1-46.4), 7.3% (95%CI:6.0-8.8), respectively. The UGT1A1 rs4148323 variant had a MAF of 3.5% (95%CI:2.6-4.6). In the CYP2B6 gene, 109 individuals were homozygous for the rs3745274 (poor metaboliser) variant, with a MAF of 39.6% (95%CI:37.0-42.3), while the rs34097093 and rs28399499 variants had no individuals homozygous for the variant (MAF: 0.2% [95%CI:0-0.5] (poor/intermediate metaboliser), and 0.1% [95%CI:0-0.4] (poor/intermediate metaboliser), respectively). The MAFs of the CYP2C19 rs12769205 (poor/intermediate metaboliser), rs4244285 (poor/intermediate metaboliser), rs3758581 (poor/intermediate metaboliser), and rs4986893 (poor/intermediate metaboliser) variants were 41.9% (95%CI:39.3-44.6), 41.9% (95%CI:39.2-44.7), 9.7% (95%CI:8.2-11.4), and 0.5% [(95%CI:0.2-1.1), respectively. Most variants showed significant differences compared to global populations, with some exhibiting higher frequencies, particularly when compared to Europeans. CYP2C19 rs12769205 and rs4244285 exhibited higher MAFs in Sri Lankans compared to both other South Asians and Europeans. The NAT2 rs1041983, NAT2 rs1799931, CYP2C19 rs4986893, CYP2C19 rs3758581, and CYP2B6 rs3745274 variants demonstrated significantly higher MAFs than in Europeans but not significantly different from South Asians.This preliminary study identifies variants in NAT2, UGT1A1, CYP2B6, and CYP2C19 genes relevant to the metabolism of anti-TB drugs, antiretrovirals, and voriconazole among Sri Lankans. Several variants, including CYP2C19 rs12769205 and rs4244285, showed higher MAFs, particularly in comparison to European populations, indicating potential differences in drug response. However, the nature of the study limits the ability to explore clinical correlations with the genotypes, therefore further research focusing on clinical correlation and functional validation is required.CONCLUSIONThis preliminary study identifies variants in NAT2, UGT1A1, CYP2B6, and CYP2C19 genes relevant to the metabolism of anti-TB drugs, antiretrovirals, and voriconazole among Sri Lankans. Several variants, including CYP2C19 rs12769205 and rs4244285, showed higher MAFs, particularly in comparison to European populations, indicating potential differences in drug response. However, the nature of the study limits the ability to explore clinical correlations with the genotypes, therefore further research focusing on clinical correlation and functional validation is required. Anti-infective medicines are crucial for treating infections, but improper dosing can cause toxicity, resistance and treatment failure. Pharmacogenomics can address genetic variations affecting drug efficacy and safety. Despite the high burden of diseases like TB and HIV in Sri Lanka and South Asia, pharmacogenomic data for these populations are limited. This study aims to fill this gap by investigating pharmacogenomic variants in a South Asian population from Sri Lankan. Pharmacogenomic data on anti-infective medicines were obtained from the PharmGKB database, selecting variants with evidence levels 1 A, 1B, 2 A, and 2B. Sri Lankan genetic data were sourced from an anonymized database of 670 Sri Lankans maintained by the Centre for Genetics and Genomics, Faculty of Medicine, University of Colombo. MAFs were compared between Sri Lankan sub-populations and global data from gnomAD, with statistical significance set at p < 0.05. MAFs of NAT2 gene rs1041983 and rs1799931 variants were, 43.7% (95%CI:41.1-46.4), 7.3% (95%CI:6.0-8.8), respectively. The UGT1A1 rs4148323 variant had a MAF of 3.5% (95%CI:2.6-4.6). In the CYP2B6 gene, 109 individuals were homozygous for the rs3745274 (poor metaboliser) variant, with a MAF of 39.6% (95%CI:37.0-42.3), while the rs34097093 and rs28399499 variants had no individuals homozygous for the variant (MAF: 0.2% [95%CI:0-0.5] (poor/intermediate metaboliser), and 0.1% [95%CI:0-0.4] (poor/intermediate metaboliser), respectively). The MAFs of the CYP2C19 rs12769205 (poor/intermediate metaboliser), rs4244285 (poor/intermediate metaboliser), rs3758581 (poor/intermediate metaboliser), and rs4986893 (poor/intermediate metaboliser) variants were 41.9% (95%CI:39.3-44.6), 41.9% (95%CI:39.2-44.7), 9.7% (95%CI:8.2-11.4), and 0.5% [(95%CI:0.2-1.1), respectively. Most variants showed significant differences compared to global populations, with some exhibiting higher frequencies, particularly when compared to Europeans. CYP2C19 rs12769205 and rs4244285 exhibited higher MAFs in Sri Lankans compared to both other South Asians and Europeans. The NAT2 rs1041983, NAT2 rs1799931, CYP2C19 rs4986893, CYP2C19 rs3758581, and CYP2B6 rs3745274 variants demonstrated significantly higher MAFs than in Europeans but not significantly different from South Asians. This preliminary study identifies variants in NAT2, UGT1A1, CYP2B6, and CYP2C19 genes relevant to the metabolism of anti-TB drugs, antiretrovirals, and voriconazole among Sri Lankans. Several variants, including CYP2C19 rs12769205 and rs4244285, showed higher MAFs, particularly in comparison to European populations, indicating potential differences in drug response. However, the nature of the study limits the ability to explore clinical correlations with the genotypes, therefore further research focusing on clinical correlation and functional validation is required. Abstract Background Anti-infective medicines are crucial for treating infections, but improper dosing can cause toxicity, resistance and treatment failure. Pharmacogenomics can address genetic variations affecting drug efficacy and safety. Despite the high burden of diseases like TB and HIV in Sri Lanka and South Asia, pharmacogenomic data for these populations are limited. This study aims to fill this gap by investigating pharmacogenomic variants in a South Asian population from Sri Lankan. Methods Pharmacogenomic data on anti-infective medicines were obtained from the PharmGKB database, selecting variants with evidence levels 1 A, 1B, 2 A, and 2B. Sri Lankan genetic data were sourced from an anonymized database of 670 Sri Lankans maintained by the Centre for Genetics and Genomics, Faculty of Medicine, University of Colombo. MAFs were compared between Sri Lankan sub-populations and global data from gnomAD, with statistical significance set at p < 0.05. Results MAFs of NAT2 gene rs1041983 and rs1799931 variants were, 43.7% (95%CI:41.1–46.4), 7.3% (95%CI:6.0-8.8), respectively. The UGT1A1 rs4148323 variant had a MAF of 3.5% (95%CI:2.6–4.6). In the CYP2B6 gene, 109 individuals were homozygous for the rs3745274 (poor metaboliser) variant, with a MAF of 39.6% (95%CI:37.0-42.3), while the rs34097093 and rs28399499 variants had no individuals homozygous for the variant (MAF: 0.2% [95%CI:0-0.5] (poor/intermediate metaboliser), and 0.1% [95%CI:0-0.4] (poor/intermediate metaboliser), respectively). The MAFs of the CYP2C19 rs12769205 (poor/intermediate metaboliser), rs4244285 (poor/intermediate metaboliser), rs3758581 (poor/intermediate metaboliser), and rs4986893 (poor/intermediate metaboliser) variants were 41.9% (95%CI:39.3–44.6), 41.9% (95%CI:39.2–44.7), 9.7% (95%CI:8.2–11.4), and 0.5% [(95%CI:0.2–1.1), respectively. Most variants showed significant differences compared to global populations, with some exhibiting higher frequencies, particularly when compared to Europeans. CYP2C19 rs12769205 and rs4244285 exhibited higher MAFs in Sri Lankans compared to both other South Asians and Europeans. The NAT2 rs1041983, NAT2 rs1799931, CYP2C19 rs4986893, CYP2C19 rs3758581, and CYP2B6 rs3745274 variants demonstrated significantly higher MAFs than in Europeans but not significantly different from South Asians. Conclusion This preliminary study identifies variants in NAT2, UGT1A1, CYP2B6, and CYP2C19 genes relevant to the metabolism of anti-TB drugs, antiretrovirals, and voriconazole among Sri Lankans. Several variants, including CYP2C19 rs12769205 and rs4244285, showed higher MAFs, particularly in comparison to European populations, indicating potential differences in drug response. However, the nature of the study limits the ability to explore clinical correlations with the genotypes, therefore further research focusing on clinical correlation and functional validation is required. |
| ArticleNumber | 153 |
| Audience | Academic |
| Author | Bhagya Hendalage, D. P. Sirisena, Nirmala Dissanayake, Vajira H. W. Ranasinghe, Priyanga Jeyapragasam, Hajanthy |
| Author_xml | – sequence: 1 givenname: Priyanga orcidid: 0000-0002-1522-9276 surname: Ranasinghe fullname: Ranasinghe, Priyanga email: priyanga@pharm.cmb.ac.lk organization: Department of Pharmacology, Faculty of Medicine, University of Colombo – sequence: 2 givenname: Hajanthy orcidid: 0009-0002-0802-4712 surname: Jeyapragasam fullname: Jeyapragasam, Hajanthy organization: Department of Pharmacology, Faculty of Medicine, University of Colombo – sequence: 3 givenname: Nirmala orcidid: 0000-0003-0994-6954 surname: Sirisena fullname: Sirisena, Nirmala organization: Department of Anatomy, Genetics and Biomedical Informatics, Faculty of Medicine, University of Colombo – sequence: 4 givenname: D. P. orcidid: 0009-0006-6228-6333 surname: Bhagya Hendalage fullname: Bhagya Hendalage, D. P. organization: Department of Anatomy, Genetics and Biomedical Informatics, Faculty of Medicine, University of Colombo – sequence: 5 givenname: Vajira H. W. orcidid: 0000-0002-3264-6856 surname: Dissanayake fullname: Dissanayake, Vajira H. W. organization: Department of Anatomy, Genetics and Biomedical Informatics, Faculty of Medicine, University of Colombo |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39893405$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkt1u1DAQhSNURH_gBbhAlriBi5TYTmLnCq0qfiqtVESBW2vi2KlL1t7aSdt9Bx6a2d0WdRGqUKTEGn_n2Jk5h9meD95k2UtaHFMq63eJMimavGBVTouKy_zmSXZAS0Fzxnm592C9nx2mdFkUVEjWPMv2eSMbXhbVQfbrywXEBejQGx8WTpNlDNYNzvckWHIN0YEfEwFrjR7XVWOt06BXBHxHxnDrtBtXaxY5lzu_4a4NWZgOt7xJxHkCJIVpvCCzhHZkGZbTAKMLntgYFuQ8OjIH_xOeZ08tDMm8uPseZd8_fvh28jmfn306PZnNc12XcsQ3gOhMV1shast1WxrGoYSCsq7gdWEFb62oaF0WXFhZG9FaU0FTA9W6Y5ofZadb3y7ApVpGt4C4UgGc2hRC7BXE0enBKEFZW5bQVBKPoUzIhjVd1_KuaaU2TKLX-63Xcmrxn7XxY4Rhx3R3x7sL1YdrRXEYdVUV6PDmziGGq8mkUS1c0mYYwJswJcVpzSpRiw36eov2gHfDZge01GtczSSrpGSCc6SO_0Hh0xmcMGYIB2x2BW93BMiM5nbsYUpJnZ5__X_27Mcu--phb_405T5-CMgtoGNIKRqrME2bZOCN3aBoodZJV9ukK0y62iRd3aCU_SW9d39UxLeihLDvTVSXYYoes_aY6jcBtBHj |
| CitedBy_id | crossref_primary_10_1016_j_diagmicrobio_2025_117005 |
| Cites_doi | 10.1097/FPC.0000000000000277 10.1155/2022/8266878 10.1155/2022/8266878 10.1002/prp2.665 10.1186/s12879-018-3462-5 10.1002/phar.1400 10.31357/fhss/vjhss.v09i02.11 10.1186/s12879-024-09638-w 10.2217/14622416.9.3.311 10.4103/0971-6866.124361 10.1533/9781908818348.305 10.4103/0974-777X.56249 10.1002/gepi.21711 10.1186/s12981-023-00572-6 10.3389/fphar.2023.1189976 10.1371/journal.pone.0257424 10.4103/0971-5916.174549 10.1186/s40246-024-00674-w 10.2217/pgs-2023-0149 10.22159/ijap.2021v13i1.39540 10.1002/cpt.583 10.5603/PJNNS.a2023.0014 10.4038/cmj.v51i1.1369 10.3390/ijms21175975 10.2217/pgs-2022-0026 10.4103/0970-2113.44400 10.1002/cpt.1477 10.1007/s40495-018-0131-8 10.1097/FPC.0000000000000182 10.1093/hmg/ddq281 10.1093/bib/bbaa292 10.2174/1389200215666140605130935 10.1089/aid.2015.0048 10.1002/cpt.911 10.1111/j.1365-2125.2012.04288.x 10.1186/s40248-018-0122-y 10.3389/fgene.2021.652704 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2025 2025. The Author(s). COPYRIGHT 2025 BioMed Central Ltd. The Author(s) 2025 2025 |
| Copyright_xml | – notice: The Author(s) 2025 – notice: 2025. The Author(s). – notice: COPYRIGHT 2025 BioMed Central Ltd. – notice: The Author(s) 2025 2025 |
| DBID | C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM IOV ISR 7X8 5PM DOA |
| DOI | 10.1186/s12879-025-10538-w |
| DatabaseName | Springer Nature OA Free Journals CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Gale In Context: Opposing Viewpoints Gale In Context: Science MEDLINE - Academic PubMed Central (Full Participant titles) Directory of Open Access Journals (DOAJ) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1471-2334 |
| EndPage | 12 |
| ExternalDocumentID | oai_doaj_org_article_712b44a958cb41278929ddb3d9b8ce28 PMC11786550 A825882733 39893405 10_1186_s12879_025_10538_w |
| Genre | Journal Article |
| GeographicLocations | Sri Lanka |
| GeographicLocations_xml | – name: Sri Lanka |
| GroupedDBID | --- 0R~ 23N 2WC 53G 5VS 6J9 6PF 7X7 88E 8C1 8FI 8FJ AAFWJ AAJSJ AASML AAWTL ABDBF ABUWG ACGFO ACGFS ACIHN ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AEUYN AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR IOV ISR ITC KQ8 M1P M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB AAYXX AFFHD CITATION ALIPV CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c648t-c6aa7ded6f776f3cb4e23a4a012d0360f73bf75164037f86e7bfe5a96a1ccd2c3 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 1 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001412620700002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1471-2334 |
| IngestDate | Mon Nov 10 04:33:01 EST 2025 Tue Nov 04 02:05:36 EST 2025 Sun Nov 09 12:58:32 EST 2025 Sat Nov 29 13:52:24 EST 2025 Tue Nov 04 18:17:34 EST 2025 Thu Nov 13 16:02:26 EST 2025 Thu Nov 13 16:02:49 EST 2025 Mon Jul 21 06:04:13 EDT 2025 Tue Nov 18 21:58:12 EST 2025 Sat Nov 29 04:42:44 EST 2025 Sat Sep 06 07:26:30 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Anti-infectives Tuberculosis HIV Sri Lanka Voriconazole South Asia Pharmacogenomics |
| Language | English |
| License | 2025. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c648t-c6aa7ded6f776f3cb4e23a4a012d0360f73bf75164037f86e7bfe5a96a1ccd2c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0009-0002-0802-4712 0009-0006-6228-6333 0000-0002-1522-9276 0000-0003-0994-6954 0000-0002-3264-6856 |
| OpenAccessLink | https://doaj.org/article/712b44a958cb41278929ddb3d9b8ce28 |
| PMID | 39893405 |
| PQID | 3162576750 |
| PQPubID | 23479 |
| PageCount | 12 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_712b44a958cb41278929ddb3d9b8ce28 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11786550 proquest_miscellaneous_3162576750 gale_infotracmisc_A825882733 gale_infotracacademiconefile_A825882733 gale_incontextgauss_ISR_A825882733 gale_incontextgauss_IOV_A825882733 pubmed_primary_39893405 crossref_citationtrail_10_1186_s12879_025_10538_w crossref_primary_10_1186_s12879_025_10538_w springer_journals_10_1186_s12879_025_10538_w |
| PublicationCentury | 2000 |
| PublicationDate | 2025-02-01 |
| PublicationDateYYYYMMDD | 2025-02-01 |
| PublicationDate_xml | – month: 02 year: 2025 text: 2025-02-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | BMC infectious diseases |
| PublicationTitleAbbrev | BMC Infect Dis |
| PublicationTitleAlternate | BMC Infect Dis |
| PublicationYear | 2025 |
| Publisher | BioMed Central BioMed Central Ltd BMC |
| Publisher_xml | – name: BioMed Central – name: BioMed Central Ltd – name: BMC |
| References | 10538_CR7 10538_CR3 PD Roy (10538_CR32) 2008; 9 A Owusu Obeng (10538_CR41) 2014; 34 D Kabbani (10538_CR45) 2023; 14 W Senaratne (10538_CR31) 2009; 51 U Amstutz (10538_CR47) 2018; 103 S Sri Ranganathan (10538_CR11) 2021; 16 SL Chan (10538_CR16) 2016; 26 10538_CR28 R Hassan (10538_CR6) 2021; 22 10538_CR27 IS Hamadeh (10538_CR9) 2017; 27 Z Desta (10538_CR40) 2019; 106 G Stocco (10538_CR22) 2020; 21 TW Kang (10538_CR36) 2010; 19 Y Bao (10538_CR8) 2018; 4 C Rodrigo (10538_CR15) 2009; 1 Ł Suprewicz (10538_CR25) 2023; 57 10538_CR20 B Basnyat (10538_CR14) 2018 10538_CR21 10538_CR43 TDP Tharanga (10538_CR19) 2013; 19 10538_CR24 P Ranasinghe (10538_CR17) 2022; 23 10538_CR26 C Sukasem (10538_CR10) 2012; 74 S SeyedAlinaghi (10538_CR5) 2023; 20 FN Cho (10538_CR29) 2024; 24 CR Röhrich (10538_CR39) 2016; 32 K Fukunaga (10538_CR48) 2021; 12 A Giacomelli (10538_CR33) 2018; 18 P Ranasinghe (10538_CR18) 2023; 24 P Panagopoulos (10538_CR37) 2017; 10 L Baietto (10538_CR23) 2014; 15 KA Phillips (10538_CR46) 2014; 16 B Dalal (10538_CR34) 2015; 142 B Moriyama (10538_CR44) 2017; 102 10538_CR38 D Behera (10538_CR4) 2006; 23 X Dai (10538_CR35) 2013; 37 S Chuwongwattana (10538_CR42) 2020; 8 10538_CR30 10538_CR1 10538_CR2 10538_CR13 10538_CR12 |
| References_xml | – volume: 27 start-page: 190 issue: 5 year: 2017 ident: 10538_CR9 publication-title: Pharmacogenet Genomics doi: 10.1097/FPC.0000000000000277 – ident: 10538_CR30 doi: 10.1155/2022/8266878 10.1155/2022/8266878 – volume: 8 start-page: e00665 issue: 6 year: 2020 ident: 10538_CR42 publication-title: Pharmacol Res Perspect doi: 10.1002/prp2.665 – volume: 18 start-page: 1 issue: 1 year: 2018 ident: 10538_CR33 publication-title: BMC Infect Dis doi: 10.1186/s12879-018-3462-5 – volume: 34 start-page: 703 issue: 7 year: 2014 ident: 10538_CR41 publication-title: Pharmacother J Hum Pharmacol Drug Ther doi: 10.1002/phar.1400 – ident: 10538_CR12 doi: 10.31357/fhss/vjhss.v09i02.11 – volume: 24 start-page: 1 issue: 1 year: 2024 ident: 10538_CR29 publication-title: BMC Infect Dis doi: 10.1186/s12879-024-09638-w – volume: 9 start-page: 311 issue: 3 year: 2008 ident: 10538_CR32 publication-title: Pharmacogenomics doi: 10.2217/14622416.9.3.311 – volume: 19 start-page: 392 issue: 4 year: 2013 ident: 10538_CR19 publication-title: Indian J Hum Genet doi: 10.4103/0971-6866.124361 – ident: 10538_CR2 – ident: 10538_CR3 doi: 10.1533/9781908818348.305 – volume: 1 start-page: 93 issue: 2 year: 2009 ident: 10538_CR15 publication-title: J Glob Infect Dis doi: 10.4103/0974-777X.56249 – volume: 10 start-page: 205 year: 2017 ident: 10538_CR37 publication-title: Pharmacogenomics Pers Med – ident: 10538_CR7 – volume: 37 start-page: 293 issue: 3 year: 2013 ident: 10538_CR35 publication-title: Genet Epidemiol doi: 10.1002/gepi.21711 – ident: 10538_CR21 – volume: 20 start-page: 1 issue: 1 year: 2023 ident: 10538_CR5 publication-title: AIDS Res Ther doi: 10.1186/s12981-023-00572-6 – volume: 14 start-page: 1189976 year: 2023 ident: 10538_CR45 publication-title: Front Pharmacol doi: 10.3389/fphar.2023.1189976 – volume: 16 start-page: e0257424 issue: 9 year: 2021 ident: 10538_CR11 publication-title: PLoS One doi: 10.1371/journal.pone.0257424 – volume: 142 start-page: 663 issue: 6 year: 2015 ident: 10538_CR34 publication-title: Indian J Med Res doi: 10.4103/0971-5916.174549 – ident: 10538_CR24 doi: 10.1186/s40246-024-00674-w – ident: 10538_CR27 – volume: 16 start-page: 251 issue: 3 year: 2014 ident: 10538_CR46 publication-title: Genet Med off J Am Coll Med Genet – volume: 24 start-page: 809 issue: 15 year: 2023 ident: 10538_CR18 publication-title: Pharmacogenomics doi: 10.2217/pgs-2023-0149 – ident: 10538_CR28 doi: 10.22159/ijap.2021v13i1.39540 – volume: 102 start-page: 45 issue: 1 year: 2017 ident: 10538_CR44 publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.583 – volume: 57 start-page: 14 issue: 1 year: 2023 ident: 10538_CR25 publication-title: Neurol Neurochir Pol doi: 10.5603/PJNNS.a2023.0014 – volume: 51 start-page: 9 issue: 1 year: 2009 ident: 10538_CR31 publication-title: Ceylon Med J doi: 10.4038/cmj.v51i1.1369 – ident: 10538_CR13 – volume: 21 start-page: 5975 issue: 17 year: 2020 ident: 10538_CR22 publication-title: Int J Mol Sci doi: 10.3390/ijms21175975 – ident: 10538_CR1 – ident: 10538_CR38 – volume: 23 start-page: 917 issue: 16 year: 2022 ident: 10538_CR17 publication-title: Pharmacogenomics doi: 10.2217/pgs-2022-0026 – volume: 23 start-page: 103 issue: 3 year: 2006 ident: 10538_CR4 publication-title: Lung India doi: 10.4103/0970-2113.44400 – volume: 106 start-page: 726 issue: 4 year: 2019 ident: 10538_CR40 publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.1477 – volume: 4 start-page: 171 issue: 3 year: 2018 ident: 10538_CR8 publication-title: Curr Pharmacol Rep doi: 10.1007/s40495-018-0131-8 – volume: 26 start-page: 28 issue: 1 year: 2016 ident: 10538_CR16 publication-title: Pharmacogenet Genomics doi: 10.1097/FPC.0000000000000182 – ident: 10538_CR20 – volume: 19 start-page: 3672 issue: 18 year: 2010 ident: 10538_CR36 publication-title: Hum Mol Genet doi: 10.1093/hmg/ddq281 – volume: 22 start-page: bbaa292 issue: 4 year: 2021 ident: 10538_CR6 publication-title: Brief Bioinform doi: 10.1093/bib/bbaa292 – volume: 15 start-page: 581 issue: 6 year: 2014 ident: 10538_CR23 publication-title: Curr Drug Metab doi: 10.2174/1389200215666140605130935 – volume: 32 start-page: 529 issue: 6 year: 2016 ident: 10538_CR39 publication-title: AIDS Res Hum Retroviruses doi: 10.1089/aid.2015.0048 – volume: 103 start-page: 210 issue: 2 year: 2018 ident: 10538_CR47 publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.911 – volume: 74 start-page: 1005 issue: 6 year: 2012 ident: 10538_CR10 publication-title: Br J Clin Pharmacol doi: 10.1111/j.1365-2125.2012.04288.x – ident: 10538_CR26 – ident: 10538_CR43 – year: 2018 ident: 10538_CR14 publication-title: Multidiscip Respir Med doi: 10.1186/s40248-018-0122-y – volume: 12 start-page: 652704 year: 2021 ident: 10538_CR48 publication-title: Front Genet doi: 10.3389/fgene.2021.652704 |
| SSID | ssj0017829 |
| Score | 2.4213133 |
| Snippet | Background
Anti-infective medicines are crucial for treating infections, but improper dosing can cause toxicity, resistance and treatment failure.... Anti-infective medicines are crucial for treating infections, but improper dosing can cause toxicity, resistance and treatment failure. Pharmacogenomics can... Background Anti-infective medicines are crucial for treating infections, but improper dosing can cause toxicity, resistance and treatment failure.... Abstract Background Anti-infective medicines are crucial for treating infections, but improper dosing can cause toxicity, resistance and treatment failure.... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 153 |
| SubjectTerms | Adult Anti-infective agents Anti-Infective Agents - adverse effects Anti-Infective Agents - pharmacology Anti-Infective Agents - therapeutic use Anti-infectives Arylamine N-Acetyltransferase - genetics Dosage and administration Female Genetic aspects Genetic Variation HIV Humans Infectious Diseases Internal Medicine Male Medical Microbiology Medicine Medicine & Public Health Middle Aged Parasitology Pharmacogenetics Pharmacogenomic Variants Pharmacogenomics Pharmacology, Experimental Physiological aspects Polymorphism, Single Nucleotide South Asia South Asian People - genetics Sri Lanka Tropical Medicine Tuberculosis |
| SummonAdditionalLinks | – databaseName: SpringerLINK dbid: RSV link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagIMSF9yNQkEFIHCDqJk7i-LggKpBKqbpQ9WY5jl0iIKk22S39D_xoZhwnIgUqwSWHeGLJk3nKM98Q8iwSqSkKEYWccUhQIqtDJVgZsplWVseiZNrhzO7w3d388FDs-aawdqh2H64knaV2ap1nWy1YUi5CHL8KMQGo6clFcgncXY7quL84GO8OwOeJoT3mj99NXJBD6v_dHv_ikM4WS565MXWOaPv6_x3hBrnmA0867yXlJrlg6lvkynt_tX6b_NjzINaI2vqt0rSf5g3b08bSNaTUWDFDlav_wLcGwSeUPqWqLmnXfId9ulOkBboq9EVea0OH2_uWVjVVtMWZfXSOvZv0eJweRrHNhS6WFd1R9Rd1h3zafvPx9dvQj2oIdZbkHTyV4qUpM8t5ZpkuEhMzlShwfyX4yJnlrLA8hdxsxrjNM8MLa1IlMhVpXcaa3SUbdVOb-4TaaGZFYstCQWSaWthDx0YzrhDmRxkWkGj4e1J7HHMcp_FVunwmz2TPZglslo7N8iQgL8ZvjnsUj3OpX6FQjJSIwO1eNMsj6RVa8igukkSJNIfDRthPDIJdFqwURa5NnAfkKYqURIyNGot4jtSqbeW7DwdyDlk5JDacsb8RLfYnRM89kW3goPBn-8YJYBdid00oNyeUYCn0ZPnJIN4Sl7C8rjbNqpUsyjDxhOgxIPd6cR9PzwSEtBDWBySfKMKEPdOVuvrsgMoj0MUsxU1fDvogvYlsz-H_g38jf0iuxqhSrpR-k2x0y5V5RC7rdVe1y8fONvwEh2ljOg priority: 102 providerName: Springer Nature |
| Title | Pharmacogenomic profiling of variants affecting efficacy and toxicity of anti-infective medicines in a south Asian population from Sri Lanka |
| URI | https://link.springer.com/article/10.1186/s12879-025-10538-w https://www.ncbi.nlm.nih.gov/pubmed/39893405 https://www.proquest.com/docview/3162576750 https://pubmed.ncbi.nlm.nih.gov/PMC11786550 https://doaj.org/article/712b44a958cb41278929ddb3d9b8ce28 |
| Volume | 25 |
| WOSCitedRecordID | wos001412620700002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVADU databaseName: Open Access: BioMedCentral Open Access Titles customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: RBZ dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.biomedcentral.com/search/ providerName: BioMedCentral – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: DOA dateStart: 20010101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: M~E dateStart: 20010101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: 7X7 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: BENPR dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: 8C1 dateStart: 20090101 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: PIMPY dateStart: 20090101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVAVX databaseName: SpringerLINK Contemporary 1997-Present customDbUrl: eissn: 1471-2334 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0017829 issn: 1471-2334 databaseCode: RSV dateStart: 20011201 isFulltext: true titleUrlDefault: https://link.springer.com/search?facet-content-type=%22Journal%22 providerName: Springer Nature |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1fb9MwELdgIMQL4u8ojMogJB4gWh0ncfzYTZuYtJWqhak8WY5jQwSkU9N27DvwoblzkmoZYrzwYinx1Wruzr47-e53hLxmMrZZJlkguIAAhTkTaMnzgA-MdiaUOTceZ_ZYjEbpbCbHl1p9YU5YDQ9cM25XsDCLIi3j1GQRw7pNWCDPeC6z1NjQl_mC19MGU839Adg92ZbIpMluBaewkAG2bgV_Arb4eccMebT-P8_kS0bpasLklVtTb4wO75N7jRdJh_W_f0Bu2PIhuXPS3JM_Ir_GDSI1QrD-KAytW3PDWnTu6BriY0x_odonc-Bbi0gS2lxQXeZ0Of8J6ywvkBboiqDJ2Fpb2l7FV7QoqaYVNuCjQyzEpGebVmAUa1bodFHQY11-04_Jp8ODj_vvg6bvQmCSKF3CqLXIbZ44IRLHge825DrSYMtyMHgDJ3jmRAyB1oALlyZWZM7GWiaaGZOHhj8hW-W8tE8JdWzgZOTyTIObGTtYw4TWcKERs0db3iOsFYMyDSg59sb4rnxwkiaqFp0C0SkvOnXeI283vzmrITmupd5D6W4oEU7bvwAlU42SqX8pWY-8Qt1QCJhRYkbOF72qKnX04VQNIcSGKEVw_jei6aRD9KYhcnP4UJBsXQUB7EIgrg7lTocStr3pTL9s9VThFObKlXa-qhRnCUaR4Ar2yHatt5uv5xL8U_DReyTtaHSHPd2ZsvjqUccZbKokxkXftcqvmvOuuob_z_4H_5-TuyFuXp8tv0O2louVfUFum_WyqBZ9clPMhB9TGNN91ie39g5G40nfHwrwND46GX-Gp8n09DfIn2T8 |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELagIMqFd2GhgEFIHCBiEydxfFwQVSu2S9UtVW-W49glApJqk93S_8CPZsZ5iBSoBJcc4oklT-Ypz3xDyAtfRCZNhe9xxiFB8a32lGCZx8ZaWR2IjGmHMzvls1lydCT22qawqqt2764knaV2ap3EbyqwpFx4OH4VYgJQ09PL5EoIHgsL-fbnh_3dAfg80bXH_PG7gQtySP2_2-NfHNL5YslzN6bOEW3d_L8j3CI32sCTThpJuU0umeIOubbbXq3fJT_2WhBrRG39lmvaTPOG7Wlp6QpSaqyYocrVf-Bbg-ATSp9RVWS0Lr_DPvUZ0gJd7rVFXitDu9v7iuYFVbTCmX10gr2b9KSfHkaxzYXOFzmdquKLukc-bb0_eLfttaMaPB2HSQ1PpXhmsthyHlum09AETIUK3F8GPnJsOUstjyA3GzNuk9jw1JpIiVj5WmeBZhtkrSgL84BQ64-tCG2WKohMIwt76MBoxhXC_CjDRsTv_p7ULY45jtP4Kl0-k8SyYbMENkvHZnk6Iq_6b04aFI8Lqd-iUPSUiMDtXpSLY9kqtOR-kIahElECh_WxnxgEO0tZJtJEmyAZkecoUhIxNgos4jlWy6qSOx8P5QSyckhsOGN_I5rvD4hetkS2hIPCn20aJ4BdiN01oNwcUIKl0IPlZ514S1zC8rrClMtKMj_GxBOixxG534h7f3omIKSFsH5EkoEiDNgzXCnyzw6o3AddjCPc9HWnD7I1kdUF_H_4b-RPyfr2we5UTndmHx6R6wGqlyur3yRr9WJpHpOrelXn1eKJsxM_AS2pZh4 |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9NAEF5BQRUX3o9AgQUhcaBWY6_t9R7DI6IihIhA1dtqvY9iAXYUOyn9D_xoZvyI6gKVEJccvOONdjyzM6OZ-YaQZ76IbJoK3-OMQ4DiO-0pwYzHhlo5HQjDdI0zO-HTaXJ4KGanuvjravcuJdn0NCBKU17tLYxrVDyJ90q4VbnwcBQr-AegsscXyaUQhwZhvD4_2OQRwP6JrlXmj-_1zFGN2v_73XzKOJ0tnDyTPa2N0vja_x_nOrnaOqR01EjQDXLB5jfJ9vs25X6L_Jy14NaI5vo907SZ8g1_RQtH1xBqYyUNVXVdCD61CEqh9AlVuaFV8QP2qU6QFugyry3-WlvaZfVLmuVU0RJn-dER9nTSxWaqGMX2FzpfZnSi8q_qNvk8fvPp1VuvHeHg6ThMKvhVihtrYsd57JhOQxswFSowiwZs59BxljoeQcw2ZNwlseWps5ESsfK1NoFmd8hWXuT2HqHOHzoROpMq8FgjB3vowGrGFcL_KMsGxO--pNQtvjmO2fgm6zgniWXDZglsljWb5fGAvNi8s2jQPc6lfokCsqFEZO76QbE8kq2iS-4HaRgqESVwWB_7jEHgTcqMSBNtg2RAnqJ4ScTeyLG450itylLufziQI4jWIeDhjP2NaP6xR_S8JXIFHBS-bNNQAexCTK8e5U6PEm4Q3Vt-0om6xCUsu8ttsSol82MMSMGrHJC7jehvTs8EuLrg7g9I0lOKHnv6K3n2pQYw90Ev4wg33e10Q7ZXZ3kO_-__G_ljsj17PZaT_em7B-RKgNpVV9vvkK1qubIPyWW9rrJy-ai-Mn4B_gtvAg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacogenomic+profiling+of+variants+affecting+efficacy+and+toxicity+of+anti-infective+medicines+in+a+south+Asian+population+from+Sri+Lanka&rft.jtitle=BMC+infectious+diseases&rft.au=Ranasinghe%2C+Priyanga&rft.au=Jeyapragasam%2C+Hajanthy&rft.au=Sirisena%2C+Nirmala&rft.au=Bhagya+Hendalage%2C+D.+P&rft.date=2025-02-01&rft.pub=BioMed+Central+Ltd&rft.issn=1471-2334&rft.eissn=1471-2334&rft.volume=25&rft.issue=1&rft_id=info:doi/10.1186%2Fs12879-025-10538-w&rft.externalDocID=A825882733 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1471-2334&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1471-2334&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1471-2334&client=summon |